MCRT Webcast: Minimal Residual Disease (MRD) Essentials: How Should Patients Interpret Results?- August 29, 2020 image

MCRT Webcast: Minimal Residual Disease (MRD) Essentials: How Should Patients Interpret Results?- August 29, 2020

Aug 29, 2020
09:00AM - 03:00PM MDT
Online Event
Overview

“As our drugs got better, our need to measure got more important.”

Dr. Jeffrey Wolf, UC San Francisco

Minimal residual disease (MRD) is fast becoming a standard in myeloma by which to measure the effectiveness of treatment and understand prognosis estimates.  What is the significance of being MRD-negative or MRD-positive?  How does each state determine the next steps of therapy?  What are the possible changes in how MRD tests are administered?  These and many other questions were addressed in the Myeloma Crowd Round Table Interactive Webcast held on Saturday, August 29, 2020.

Drs. Rafael Fonseca and Jeffrey Wolf discussed how patients should interpret results of minimal residual testing:

 

Thanks to our Round Table sponsors

User uploaded media

User uploaded media

User uploaded media

User uploaded media  

User uploaded media

User uploaded media

 User uploaded media

User uploaded media

User uploaded media

 

Highlights
Agenda
09:00 AM
Round Table
Dr. Jeffrey Wolf and Dr. Rafael Fonseca
Speakers & Moderators
Healthtree contact Rafael Fonseca, MD

Rafael Fonseca, MD

Rafael Fonseca, MD, is the Getz Family Professor of Cancer, Professor of Medicine, interim Executive Director of the Mayo Clinic Comprehensive Cancer Center…

Rafael Fonseca, MD, is the Getz Family Professor of Cancer, Professor of Medicine, Chief Innovation Officer, and a consultant in the Division of Hematology/Oncology at the Mayo Clinic in Arizona. He is a member of the Mayo Clinic Board of Governors and Board of Trustees. He earned his MD at Universidad Anahuac, Mexico. He completed a residency in Internal Medicine at the University of Miami, FL, and a fellowship in Hematology and Medical Oncology at Mayo Graduate School of Medicine, Rochester, MN. He was named a Clinical Investigator for the Damon Runyon Cancer Research Fund. Dr Fonseca’s practice and research have focused on the diagnosis and treatment of plasma cell disorders. He leads the multiple myeloma team in its efforts to develop a better understanding of the disease and its impact on patients. In his laboratory, Dr Fonseca has led his team of researchers to better understand the genetic nature of malignant plasma cells, real world evidence analysis, myeloma bone disease, prognostic markers, pharmacoeconomics and development of new therapies for the disease. He is an active participant and leader of myeloma clinical trials. He also has served as consultant to multiple companies including AbbVie, Adaptive Biotechnologies, Amgen, Apple, BMS, GSK, Janssen, Karyopharm, Pfizer, Regeneron, and Sanofi. He is a member of the Scientific Advisory Board of Caris Life Sciences, Ryght, Fortvita and Xenagos. He is a member of the Board of Directors for Antengene. He holds the patent for FISH prognostication in myeloma. He has over 400 peer reviewed publications with an associated H index of 135 with 73,278 citations (Google Scholar October 2026). Throughout his training and career, Dr Fonseca has received numerous awards and honors, including the Damon Runyon Clinical Investigator Award, and the International Waldenström Macroglobulinemia Research Award. He is a Mayo Clinic Distinguished Investigator, the highest academic distinction given to investigators at his institution. He was awarded in 2023 the Cyril-Rozman prize by the Spanish Society of Hematology and Hematotherapy. He was awarded a Doctor honoris causa by the Universidad de San Pablo, Argentina in February 2023. He was inducted into the Giants of Cancer Care in 2024. Dr Fonseca holds memberships and has served in positions for organizations such as the ASCO, ASH and the International Myeloma Society. His research has been funded by the National Cancer Institute (R01, P01, SPORE, CPTAC U01), the Leukemia & Lymphoma Society, the Multiple Myeloma Research Foundation, and the Damon Runyon Cancer Research Fund, Paula and Rodger Riney Foundation and others. Dr Fonseca serves as reviewer and in editorial capacities for medical publications including Blood, Lancet, Nature Medicine, Cancer Cell, Leukemia, and the New England Journal of Medicine, among others. He has given many national and international presentations as a visiting professor.